The latest update is out from Sosei Group ( (JP:4565) ).
Nxera Pharma has entered into an agreement with Viatris Inc., granting them exclusive rights to develop and commercialize cenerimod, a novel oral S1P1 receptor modulator, in Japan and the Asia-Pacific region excluding China. This strategic move allows Viatris to hold global rights to cenerimod, which is in Phase 3 trials for systemic lupus erythematosus, potentially positioning it as a first-in-class therapy for autoimmune diseases. The deal includes an upfront payment of $10 million to Nxera, with additional milestone and royalty payments contingent on regulatory approval and sales, thereby enhancing Nxera’s shareholder value and expanding Viatris’ immunology platform.
More about Sosei Group
Nxera Pharma is a technology-driven biopharmaceutical company focused on developing specialty medicines to address unmet medical needs in Japan and globally. The company is advancing a pipeline of over 30 active programs in areas such as neurology, gastrointestinal and immunology, metabolic disorders, and rare diseases. Nxera leverages its GPCR-targeted structure-based drug discovery platform, NxWave™, to develop best- or first-in-class candidates. The company operates in key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul and is listed on the Tokyo Stock Exchange.
YTD Price Performance: -9.92%
Average Trading Volume: 614
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $531.6M
Learn more about 4565 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com